Oxford BioDynamics (OBD) is an early stage health-care service company with a patented diagnostic technology that is based on extensive research in epigenetics of gene expression and the properties of non-coding RNA.
The novel and revolutionary diagnostic technology offers a highly effective means of screening; early detection; monitoring and prognosis analysis of major diseases associated with aberrant gene expression. OBD is currently applying its technology to the investigation of cancer and cardiovascular conditions.